Should patients with minor strokes be given thrombolytics?
Xun WangQiang DongQiang DongDavid WangPublished in: Stroke and vascular neurology (2024)
Mild stroke symptoms are cited as the reason for not using tissue-type plasminogen activator in 29-43% of time-eligible patients. Previous studies suggested that not all of these patients had a good recovery or even survival to hospital discharge. Since then, stroke guidelines worldwide recommended thrombolysis in minor but disabling strokes.Dual antiplatelet treatment with aspirin and clopidogrel was more effective than aspirin alone for reducing subsequent events in patients with minor stroke if started within 24 hours of onset in both CHANCE (Clopidogrel in High-Risk Patients with Acute Non-disabling Cerebrovascular Events) and POINT (Platelet-Oriented Inhibition in New TIA and Minor Ischaemic Stroke) trials. Recently, both PRISMS (The Potential of rtPA for Ischemic Strokes With Mild Symptoms) trial and TEMPO-2(The Potential of rtPA for Ischemic Strokes With Mild Symptoms) trial showed that treatment with thrombolysis versus antiplatelet did not increase the likelihood of favourable functional outcome at 90 days among patients with minor non-disabling acute ischaemic strokes. Therefore, a narrative review on thrombolysis for patients with minor strokes from published studies may help practicing clinicians.
Keyphrases
- end stage renal disease
- pulmonary embolism
- atrial fibrillation
- ejection fraction
- acute coronary syndrome
- chronic kidney disease
- newly diagnosed
- low dose
- peritoneal dialysis
- antiplatelet therapy
- prognostic factors
- study protocol
- percutaneous coronary intervention
- randomized controlled trial
- type diabetes
- cardiovascular disease
- liver failure
- systematic review
- palliative care
- coronary artery disease
- intensive care unit
- clinical practice
- drug induced
- case control
- mechanical ventilation
- replacement therapy